Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE4
76 participants
INTERVENTIONAL
2021-12-28
2026-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lorlatinib
Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
Lorlatinib
ALK-positive NSCL treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lorlatinib
ALK-positive NSCL treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2- Participants must agree to follow the reproductive criteria. 3- Adequate Bone Marrow, Liver, Renal, Pancreatic Function
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
The First affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Hunan Provincial Tumor Hospital
Changsha, Hunan, China
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
The first hospital of jilin university
Changchun, Jilin, China
Sir Run Shaw Hospital
Hangzhou, Qiantang District, China
The Second Affiliated Hospital of PLA Air Force Medical University
Xi'an, Shaanxi, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Sichuan Cancer hospital
Chengdu, Sichuan, China
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University College of Medicine
Hangzhou, Zhejiang, China
Fudan University Shanghai Cancer Center
Shanghai, , China
CHU de Rennes - Hôpital Pontchaillou
Rennes, , France
Institut Gustave Roussy
Villejuif, , France
Healthcare Global Enterprises
Bengaluru, Karnataka, India
Bhaktivedanta Hospital & Research Institute
Thāne, Maharashtra, India
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
National University Hospital
Singapore, , Singapore
National Cancer Centre Singapore
Singapore, , Singapore
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
National Taiwan University Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B7461039
Identifier Type: -
Identifier Source: org_study_id
2023-508952-21-00
Identifier Type: REGISTRY
Identifier Source: secondary_id